Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, epigenetics, and mitosis biology in the United States and the United Kingdom. Its lead product, Plogosertib or plogo, is a PLK1 inhibitor, in solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [05/02/2025 07:08 PDT] CYCC Expected to Trade Down After Bearish Patterns Develop
• [04/11/2025 07:27 PDT] CYCC Expected to Trade Up After Bullish Patterns Develop
• [04/02/2025 13:20 PDT] Cyclacel Pharmaceuticals, Inc (NASDAQ:CYCC), Down By 100% ($0.3) From $0.304 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [03/14/2025 07:08 PDT] CYCC Expected to Trade Down After Bearish Patterns Develop